AAM Welcomes Biosimilar Access Bill
US Legislation Would Boost Prescribing And Demonstrate Savings
A US bill aimed at promoting biosimilars by encouraging greater prescribing rates and creating a shared savings demonstration program for biosimilars has been warmly welcomed by the AAM.
You may also be interested in...
A wave of recent biosimilar launches in the US has provided multi-source competition on several major brands and stands to boost the country’s biosimilars market, according to Sean McGowan, senior director of biosimilars at AmerisourceBergen.
In a busy second quarter for Teva, a COVID-19 slump acted as a correction to the related boost in demand seen in the first quarter of 2020.
ANI Pharmaceuticals has chosen its new president and CEO to replace interim chief Patrick Walsh who stepped in after the departure Arthur Przybyl earlier this year. Meanwhile, key personnel announcements have also been made by Teva and Mylan.